News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
564,738 Results
Type
Article (38824)
Company Profile (97)
Press Release (525817)
Section
Business (174393)
Career Advice (2168)
Deals (28694)
Drug Delivery (85)
Drug Development (61779)
Employer Resources (145)
FDA (13858)
Job Trends (12584)
News (285162)
Policy (27024)
Tag
Academia (2180)
Alliances (44806)
Alzheimer's disease (1067)
Approvals (13850)
Artificial intelligence (137)
Bankruptcy (260)
Best Places to Work (9888)
Breast cancer (163)
Cancer (1149)
Cardiovascular disease (89)
Career advice (1827)
Cell therapy (246)
Clinical research (48784)
Collaboration (438)
Compensation (134)
COVID-19 (2608)
C-suite (94)
Data (1158)
Diabetes (150)
Diagnostics (6332)
Earnings (71910)
Employer resources (131)
Events (84161)
Executive appointments (326)
FDA (14418)
Funding (352)
Gene therapy (160)
GLP-1 (514)
Government (3885)
Healthcare (15449)
Infectious disease (2706)
Inflammatory bowel disease (92)
Interviews (392)
IPO (12910)
Job creations (3077)
Job search strategy (1542)
Layoffs (367)
Legal (6677)
Lung cancer (160)
Lymphoma (78)
Manufacturing (184)
Medical device (10560)
Medtech (10564)
Mergers & acquisitions (15932)
Metabolic disorders (376)
Neuroscience (1337)
NextGen Class of 2024 (5255)
Non-profit (3784)
Northern California (1321)
Obesity (206)
Opinion (212)
Parkinson's disease (82)
Patents (102)
People (47060)
Phase I (14988)
Phase II (21019)
Phase III (16939)
Pipeline (472)
Postmarket research (2177)
Preclinical (6385)
Radiopharmaceuticals (223)
Rare diseases (205)
Real estate (4843)
Regulatory (17717)
Research institute (1998)
Resumes & cover letters (336)
Southern California (1117)
Startups (2865)
United States (12070)
Vaccines (666)
Weight loss (154)
Date
Today (104)
Last 7 days (451)
Last 30 days (1933)
Last 365 days (28674)
2024 (28555)
2023 (32566)
2022 (42847)
2021 (46331)
2020 (45277)
2019 (38440)
2018 (28968)
2017 (27348)
2016 (26755)
2015 (31393)
2014 (25870)
2013 (22256)
2012 (22969)
2011 (23242)
2010 (21835)
Location
Africa (832)
Arizona (137)
Asia (32324)
Australia (5609)
California (2894)
Canada (1178)
China (223)
Colorado (144)
Connecticut (169)
Europe (76640)
Florida (435)
Georgia (112)
Illinois (309)
Indiana (179)
Maryland (532)
Massachusetts (2273)
Michigan (175)
Minnesota (215)
New Jersey (940)
New York (888)
North Carolina (652)
Northern California (1321)
Ohio (119)
Pennsylvania (696)
South America (1054)
Southern California (1117)
Texas (441)
Utah (95)
Washington State (298)
564,738 Results for "chiron corporation now novartis vaccines and diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphyoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Press Releases
Alzheimer’s Diagnostic Blood Test Now Available in the UK
November 18, 2024
·
1 min read
Legal
GSK Settles Zantac Lawsuits for $2.2B, Analysts Now Shift Focus to Vaccines
The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the product liability cases regarding allegations that GSK’s heartburn drug could cause cancer. Analysts say separate concerns remain about its vaccines business.
October 10, 2024
·
2 min read
·
Tristan Manalac
Legal
Novartis Loses Appeal to Bar Entresto Generic From U.S. Market
Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.
December 5, 2024
·
2 min read
·
Tristan Manalac
Earnings
Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.
October 29, 2024
·
2 min read
·
Tristan Manalac
Vaccines
5 Late-Stage mRNA Vaccines to Watch
The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the market for cancer, influenza and more.
September 16, 2024
·
5 min read
·
Ben Hargreaves
Business
Chiron AS Establishes State-of-the-Art Research Centre in Trondheim, Norway, Advancing Environmental Surveillance
Chiron AS, a leading producer of chemical reference materials headquartered in Trondheim, Norway, is pleased to announce the establishment of a state-of-the-art research centre dedicated to the enhanced surveillance of environmental pollutants.
January 17, 2024
·
2 min read
Mergers & Acquisitions
Novartis CEO Promises More Deals of Up to $5B, With an Eye for Early Science
Novartis has disclosed roughly $19.4 billion in deals in the past five years. CEO Vas Narasimhan says there’s more to come.
November 21, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
Longhorn Vaccines and Diagnostics Composite Peptide Vaccine Combats Sepsis Related to Antimicrobial Resistant Tuberculosis
November 13, 2024
·
3 min read
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
November 18, 2024
·
2 min read
·
Nick Paul Taylor
1 of 56,474
Next
